UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

How I treat chronic myeloid leukemia in the imatinib era

Blood, 2007-10, Vol.110 (8), p.2828-2837

Goldman, John M.

2007

Volltextzugriff (PDF)

Chronic Myeloid Leukemia: A Historical Perspective

Seminars in hematology, 2010-10, Vol.47 (4), p.302-311

Goldman, John M

2010

Volltextzugriff (PDF)

Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors

Journal of clinical oncology, 2012-01, Vol.30 (3), p.232-238

2012

Volltextzugriff (PDF)

Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis

Journal of clinical oncology, 2008-07, Vol.26 (20), p.3358-3363

2008

Volltextzugriff (PDF)

Relapse and Late Mortality in 5-Year Survivors of Myeloablative Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia in First Chronic Phase

Journal of clinical oncology, 2010-04, Vol.28 (11), p.1888-1895

2010

Volltextzugriff (PDF)

Finding of Kinase Domain Mutations in Patients With Chronic Phase Chronic Myeloid Leukemia Responding to Imatinib May Identify Those at High Risk of Disease Progression

Journal of clinical oncology, 2008-10, Vol.26 (29), p.4806-4813

2008

Volltextzugriff (PDF)

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

Blood, 2003-03, Vol.101 (6), p.2368-2373

2003

Volltextzugriff (PDF)

Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia

Haematologica (Roma), 2010-02, Vol.95 (2), p.224-231

2010

Volltextzugriff (PDF)

Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia

Cancer research (Chicago, Ill.), 2005-10, Vol.65 (19), p.8912-8919

2005

Volltextzugriff (PDF)

Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia

Blood, 2007-12, Vol.110 (13), p.4614-4617

2007

Volltextzugriff (PDF)

Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase

Blood, 2010-05, Vol.115 (20), p.4018-4020

2010

Volltextzugriff (PDF)

Ponatinib for Chronic Myeloid Leukemia

The New England journal of medicine, 2012-11, Vol.367 (22), p.2148-2149

Goldman, John M

2012

Volltextzugriff (PDF)

What challenges remain in chronic myeloid leukemia research?

Haematologica (Roma), 2013-08, Vol.98 (8), p.1168-1172

2013

Volltextzugriff (PDF)

Cord blood stem cells for hematopoietic stem cell transplantation in the UK: how big should the bank be?

Haematologica (Roma), 2009-04, Vol.94 (4), p.536-541

2009

Volltextzugriff (PDF)

Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia

Blood, 2000-10, Vol.96 (8), p.2712-2716

2000

Volltextzugriff (PDF)

Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib

Blood, 2012-07, Vol.120 (2), p.291-294

2012

Volltextzugriff (PDF)

Chronic Myeloproliferative Disorders

1, 2013

Volltextzugriff (PDF)

Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms

Haematologica (Roma), 2014-05, Vol.99 (5), p.797-801

2014

Volltextzugriff (PDF)

Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure

Journal of the National Comprehensive Cancer Network, 2012-10, Vol.10 Suppl 3 (Suppl 3), p.S1-S-13

2012

Volltextzugriff (PDF)

Early detection of BCR-ABL transcripts by quantitative reverse transcriptase–polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia

Blood, 2001-03, Vol.97 (6), p.1560-1565

2001

Volltextzugriff (PDF)

Three decades of transplantation for chronic myeloid leukemia: what have we learned?

Blood, 2011-01, Vol.117 (3), p.755-763

2011

Volltextzugriff (PDF)

1 – 25 von 1.981

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.749)
Mit Volltextzugriff
(1.622)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.259)
Life Sciences & Biomedicine
(1.153)
Humans
(1.087)
Male
(567)
Female
(558)
Biological And Medical Sciences
(513)
Medical Sciences
(470)
Adult
(412)
Middle Aged
(361)
Hematology
(256)
Aged
(214)
Animals
(180)
Adolescent
(160)
Hematologic And Hematopoietic Diseases
(140)
General & Internal Medicine
(132)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(129)
Treatment Outcome
(127)
Neurosciences & Neurology
(125)
Oncology
(116)
Medicine, General & Internal
(110)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(201)
British Journal Of Haematology
(55)
The New England Journal Of Medicine
(53)
The Lancet
(37)
Arthritis And Rheumatism
(31)
Alzheimer's & Dementia
(30)
Newsweek
(30)
Journal Of Clinical Oncology
(26)
Arthritis & Rheumatology
(22)
Arthritis Care & Research
(21)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

How I treat chronic myeloid leukemia in the imatinib era

Chronic Myeloid Leukemia: A Historical Perspective

Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors

Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials

Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies

Relapse and Late Mortality in 5-Year Survivors of Myeloablative Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia in First Chronic Phase

Finding of Kinase Domain Mutations in Patients With Chronic Phase Chronic Myeloid Leukemia Responding to Imatinib May Identify Those at High Risk of Disease Progression

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia

Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia

Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia

Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase

Ponatinib for Chronic Myeloid Leukemia

What challenges remain in chronic myeloid leukemia research?

Cord blood stem cells for hematopoietic stem cell transplantation in the UK: how big should the bank be?

Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia

Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib

Chronic Myeloproliferative Disorders

Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms

Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure

Early detection of BCR-ABL transcripts by quantitative reverse transcriptase–polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia

Three decades of transplantation for chronic myeloid leukemia: what have we learned?

Suchergebnisse filtern